China SXT PharmaceuticalsSTU:2RY1 47 PS Ratio is 304.52 as of Jul. 12, 2026, which is 27089% above its 10-year median of 1.12. GuruFocus rates STU:2RY1 with a GF Score™ of 47/100 and a GF Value™ of €307.50. The stock has 7 warning signs investors should review. Among 955 Drug Manufacturers companies, China SXT Pharmaceuticals ranks better than 63.87% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, China SXT Pharmaceuticals's share price is €384.00.
China SXT Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €1.26. Hence, China SXT Pharmaceuticals's PS Ratio for today is 304.52.
Warning Sign:
China SXT Pharmaceuticals Inc stock PS Ratio (=1.53) is close to 1-year high of 1.54.
The historical rank and industry rank for China SXT Pharmaceuticals's PS Ratio or its related term are showing as below:
STU:2RY1'
s PS Ratio Range Over the Past 10 Years
Min: 0.01 Med: 1.12 Max: 2.1
Current: 1.52
During the past 10 years, China SXT Pharmaceuticals's highest PS Ratio was 2.10. The lowest was 0.01. And the median was 1.12.
STU:2RY1's PS Ratio is ranked better than 63.87% of 955
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs STU:2RY1: 1.52
China SXT Pharmaceuticals (STU:2RY1) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
China SXT Pharmaceuticals PS Ratio Related Terms
China SXT Pharmaceuticals PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China SXT Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China SXT Pharmaceuticals PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China SXT Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where China SXT Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
China SXT Pharmaceuticals's Share Price of today is €384.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China SXT Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €1.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
China SXT Pharmaceuticals (STU:2RY1) has a PS Ratio of 304.52 as of Jul. 12, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on China SXT Pharmaceuticals and its competitors. This is 27089% above median its historical median of 1.12. Over the past decade, China SXT Pharmaceuticals' PS Ratio has ranged from 0.01 to 2.10. According to the industry distribution chart, China SXT Pharmaceuticals ranks #345 out of 955 companies in the Drug Manufacturers industry, placing it in the top 36.1%.
Is China SXT Pharmaceuticals' PS Ratio too high?
China SXT Pharmaceuticals' current PS Ratio of 304.52 is 27089% above median its 10-year median of 1.12. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 2.10. The Drug Manufacturers industry median PS Ratio is 2.30. China SXT Pharmaceuticals' value of 304.52 is 13140% above this industry median. Based on the distribution chart, China SXT Pharmaceuticals ranks #345 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China SXT Pharmaceuticals has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does China SXT Pharmaceuticals' PS Ratio compare to CABR and BFRI?
According to the Drug Manufacturers industry distribution chart, China SXT Pharmaceuticals ranks #345 out of 955 companies for PS Ratio. This puts China SXT Pharmaceuticals in the upper half of its industry. The industry median PS Ratio is 2.30. China SXT Pharmaceuticals' value of 304.52 is 13140% above this benchmark. Historically, China SXT Pharmaceuticals' own PS Ratio has ranged from 0.01 to 2.10 over the past decade. While the company's 10-year median is 1.12 vs. the industry median of 2.30, China SXT Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.30, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China SXT Pharmaceuticals's current PS Ratio of 304.52 is 13140% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on China SXT Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China SXT Pharmaceuticals's current PS Ratio is 304.52, which is 27089% above median its own 10-year median of 1.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China SXT Pharmaceuticals stock overvalued right now?
China SXT Pharmaceuticals (STU:2RY1) has a current PS Ratio of 304.52. The stock's GF Value™ is €307.50, compared to a current price of €384.00 — trading 24.9% above its estimated fair value. The current PS Ratio is 304.52, which is 27089% above median its 10-year median of 1.12 and 13140% above the Drug Manufacturers industry median of 2.30. China SXT Pharmaceuticals' overall GF Score™ is 47/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For China SXT Pharmaceuticals (STU:2RY1), the current PS Ratio is 304.52 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China SXT Pharmaceuticals (STU:2RY1) Overvalued in 2026?
Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be overvalued.
The current stock price of €384.00 is trading 24.9% above its estimated GF Value™ of €307.50.
Key valuation signals for STU:2RY1:
PS Ratio: 304.52 (27089% above median its 10-year median of 1.12)
GF Value™: €307.50 vs. price of €384.00 (24.9% above fair value)
Industry Position: 13140% above the Drug Manufacturers median (#345 of 955)
No single metric tells the full story. See the STU:2RY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
47GF Score
Get the complete analysis for STU:2RY1
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2RY1 has been successfully added to your 
